4.6 Article

Anti-tumor effects of a nonsteroidal anti-inflammatory drug zaltoprofen on chondrosarcoma via activating peroxisome proliferator-activated receptor gamma and suppressing matrix metalloproteinase-2 expression

Journal

CANCER MEDICINE
Volume 7, Issue 5, Pages 1944-1954

Publisher

WILEY
DOI: 10.1002/cam4.1438

Keywords

Chondrosarcoma; MMP2; nonsteroidal anti-inflammatory drugs; PPAR gamma; zaltoprofen

Categories

Funding

  1. Japan Society for the Promotion of Science [JP15K10435, JP17K16682]
  2. Grants-in-Aid for Scientific Research [15K10435] Funding Source: KAKEN

Ask authors/readers for more resources

Surgical resection is the only treatment for chondrosarcomas, because of their resistance to chemotherapy and radiotherapy; therefore, additional strategies are crucial to treat chondrosarcomas. Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a ligand-activated transcription factor, which has been reported as a possible therapeutic target in certain malignancies including chondrosarcomas. In this study, we demonstrated that a nonsteroidal antiinflammatory drug, zaltoprofen, could induce PPAR gamma activation and elicit anti-tumor effects in chondrosarcoma cells. Zaltoprofen was found to induce expressions of PPAR gamma mRNA and protein in human chondrosarcoma SW1353 and OUMS27 cells, and induce PPAR gamma-responsible promoter reporter activities. Inhibitory effects of zaltoprofen were observed on cell viability, proliferation, migration, and invasion, and the activity of matrix metalloproteinase-2 (MMP2); these effects were dependent on PPAR gamma activation and evidenced by silencing PPAR gamma. Moreover, we showed a case of a patient with cervical chondrosarcoma (grade 2), who was treated with zaltoprofen and has been free from disease progression for more than 2 years. Histopathological findings revealed enhanced expression of PPAR gamma and reduced expression of MMP2 after administration of zaltoprofen. These findings demonstrate that zaltoprofen could be a promising drug against the malignant phenotypes in chondrosarcomas via activation of PPAR gamma and inhibition of MMP2 activity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Biochemistry & Molecular Biology

Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma

Shinji Miwa, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Kentaro Igarashi, Hiroyuki Tsuchiya

Summary: Chondrosarcomas develop resistance to standard anticancer drugs, making it challenging to control the disease. New treatment approaches, such as molecule-targeting agents and immunotherapy, are needed. Recent studies have identified promising biomarkers and therapeutic targets for chondrosarcoma, and various molecule-targeting agents and immunotherapies have shown favorable antitumor activity in clinical studies. This review summarizes recent research on biomarkers and therapeutic targets, as well as clinical studies on the treatment of chondrosarcomas.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Review Orthopedics

Large intraosseous chronic expanding hematoma after total hip arthroplasty presenting with chronic disseminated intravascular coagulation: a case report and literature review

Yuki Yamamuro, Tamon Kabata, Akihiko Takeuchi, Yoshitomo Kajino, Daisuke Inoue, Takaaki Ohmori, Junya Yoshitani, Takuro Ueno, Ken Ueoka, Atsushi Taninaka, Tomoyuki Kataoka, Yoshitomo Saiki, Hiroyuki Tsuchiya

Summary: This case report presents a rare case of a large intraosseous chronic expanding hematoma (CEH) presenting with chronic disseminated intravascular coagulation (DIC), which was successfully treated with a single-stage excision and revision THA.

BMC MUSCULOSKELETAL DISORDERS (2022)

Article Oncology

Clinical Outcomes of Limb-sparing Tumor Surgery With Vascular Reconstruction for Bone and Soft-tissue Tumors

Yohei Asano, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Shinji Miwa, Kentaro Igarashi, Yuta Taniguchi, Sei Morinaga, Kaoru Tada, Takayuki Nojima, Hiroyuki Tsuchiya

Summary: This study retrospectively investigated the clinical outcomes of limb-sparing tumor resection surgery with vascular reconstruction and discussed reconstruction methods and postoperative complications. The results showed that synthetic grafts may be recommended to reduce the graft occlusion rate. Most postoperative complications can be controlled by conservative treatment.

ANTICANCER RESEARCH (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

A Viability Analysis of Tumor-Bearing Frozen Autograft for the Reconstruction After Resection of Malignant Bone Tumors Using 99mTc-MDP Scintigraphy

Yoshihiro Araki, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Kensaku Abe, Yuta Taniguchi, Hirotaka Yonezawa, Sei Morinaga, Yohei Asano, Takayuki Nojima, Junichi Taki, Hiroyuki Tsuchiya

Summary: The viability of devitalized bone grafts in frozen autograft reconstruction after malignant bone tumor excision was evaluated using Tc-99m-MDP scans. The results showed that the viability of bone grafts recovered within 60 months postoperatively, and this method can also predict postoperative complications.

CLINICAL NUCLEAR MEDICINE (2023)

Article Cell Biology

A nonsteroidal anti-inflammatory drug, zaltoprofen, inhibits the growth of extraskeletal chondrosarcoma cells by inducing PPARγ, p21, p27, and p53

Takashi Higuchi, Akihiko Takeuchi, Seiichi Munesue, Norio Yamamoto, Katsuhiro Hayashi, Ai Harashima, Yasuhiko Yamamoto, Hiroyuki Tsuchiya

Summary: The nonsteroidal anti-inflammatory drug zaltoprofen induces the expression of PPAR gamma in human extraskeletal chondrosarcoma cells and inhibits their proliferation. Zaltoprofen treatment also inhibits tumor growth and induces tumor cell apoptosis in a mouse model of extraskeletal myxoid chondrosarcoma. These findings suggest the potential use of zaltoprofen as an effective treatment for sarcomas.

CELL CYCLE (2023)

Article Orthopedics

What Are the Complications, Function, and Survival of Tumor-devitalized Autografts Used in Patients With Limb-sparing Surgery for Bone and Soft Tissue Tumors? A Japanese Musculoskeletal Oncology Group Multi-institutional Study

Akihiko Takeuchi, Hiroyuki Tsuchiya, Nokitaka Setsu, Tabu Gokita, Yasunori Tome, Naofumi Asano, Yusuke Minami, Hiroyuki Kawashima, Suguru Fukushima, Satoshi Takenaka, Hidetatsu Outani, Tomoki Nakamura, Satoshi Tsukushi, Teruya Kawamoto, Teruki Kidani, Munehisa Kito, Hiroshi Kobayashi, Takeshi Morii, Toru Akiyama, Tomoaki Torigoe, Koji Hiraoka, Akihito Nagano, Shigeki Kakunaga, Kazuhiko Hashimoto, Makoto Emori, Hisaki Aiba, Yoshikazu Tanzawa, Takafumi Ueda, Hirotaka Kawano

Summary: Tumor-devitalized autografts are a biological reconstruction option that offers advantages such as reduced immunological response, better site match, and no need for a bone bank. However, they also have limitations including inability to assess tumor margins, limited healing potential, and decreased biomechanical strength. Limited data is available on the outcomes of this procedure, making it important for further research.

CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2023)

Editorial Material Biochemistry & Molecular Biology

Sarcoma: Molecular Pathology, Diagnostics, and Therapeutics

Shinji Miwa, Norio Yamamoto, Hiroyuki Tsuchiya

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Oncology

Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis

Yohei Asano, Norio Yamamoto, Satoru Demura, Katsuhiro Hayashi, Akihiko Takeuchi, Satoshi Kato, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Yuta Taniguchi, Sei Morinaga, Takashi Sone, Miho Okuda, Isao Matsumoto, Seiji Yano, Hiroyuki Tsuchiya

Summary: This retrospective study investigated the therapeutic effects of immune checkpoint inhibitors (ICIs) and identified predictors of favorable response and prognosis in advanced non-small-cell lung cancer (NSCLC) patients with bone metastases. The study found a response rate of 30.9% and a median survival time of 9.3 months. Factors such as female sex, use of ICIs as first-line therapy, and pretreatment neutrophil-to-lymphocyte ratio (NLR) less than 2.1 were identified as predictors of therapeutic response, while concomitant use of a bone-modifying agent, Katagiri score <= 6 points, and NLR <2.1 were identified as predictors of good prognosis.

CANCER MEDICINE (2023)

Article Oncology

Clinical Outcome of Low-Grade Myofibroblastic Sarcoma in Japan: A Multicenter Study from the Japanese Musculoskeletal Oncology Group

Munehisa Kito, Keisuke Ae, Masanori Okamoto, Makoto Endo, Kunihiro Ikuta, Akihiko Takeuchi, Naohiro Yasuda, Taketoshi Yasuda, Yoshinori Imura, Takeshi Morii, Kazutaka Kikuta, Teruya Kawamoto, Yutaka Nezu, Ichiro Baba, Shusa Ohshika, Takeshi Uehara, Takafumi Ueda, Jun Takahashi, Hirotaka Kawano

Summary: This study aimed to analyze the clinical outcomes of patients with low-grade myofibroblastic sarcoma (LGMS). Surgical treatment was the main approach, with radiotherapy considered as a viable option in cases where surgery was not feasible or may cause significant functional impairment.

CANCERS (2023)

Article Pediatrics

Outcomes of Window Therapy with Carboplatin and Ifosfamide for Pediatric Osteosarcoma: A Case Series

Hisaki Aiba, Michi Kamei, Yasuhiko Ito, Risa Takeda, Satoshi Yamada, Hideki Okamoto, Katsuhiro Hayashi, Shinji Miwa, Yohei Kawaguchi, Shiro Saito, Takao Sakai, Hideki Murakami, Hiroaki Kimura

Summary: This study reports the use of carboplatin as a substitute for cisplatin in the treatment of osteosarcoma, and the efficacy of a CBDCA-based regimen in the neoadjuvant setting was found to be limited. Therefore, it was considered insufficient for performing adequate surgery.

CHILDREN-BASEL (2023)

Article Oncology

Graft Survivals after Reconstruction Using Tumor-Bearing Frozen Bone in the Extremities

Shinji Miwa, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Kentaro Igarashi, Martin Louie S. Bangcoy, Yuta Taniguchi, Sei Morinaga, Yohei Asano, Hiroyuki Tsuchiya

Summary: This retrospective cohort study investigated predictive factors for graft survival in patients who underwent reconstructions using tumor-bearing frozen autografts after bone tumor resection. The graft survival rates at 5 years and 10 years were 83.2% and 70.2% respectively. Multivariate analysis revealed that BMI≥23.6, tibia, and freezing procedure were independently associated with graft survival. Pedicle or hemicortical freezing techniques are recommended based on the results.

CANCERS (2023)

Editorial Material Pediatrics

Special Issue: Pediatric Orthopedic Malignancy: Types, Symptoms, and Treatment

Hisaki Aiba, Shinji Miwa, Hideki Murakami, Hiroaki Kimura

CHILDREN-BASEL (2023)

No Data Available